Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: Nephros develops hemodiafiltration (HDF) products for End Stage Renal Disease (ESRD) and water filtration systems. Key products include the OLpůr MDHDF Filter Series and the Dual Stage Ultrafilter (DSU). The company is currently conducting clinical trials for its H2H module in the U.S. and has a development contract with the U.S. Department of Defense.
Key Financial Metrics
| Metric (in thousands) | Q1 2008 | Q1 2007 |
|---|---|---|
| Net Product Revenues | $387 | $296 |
| Gross Margin | $149 | $91 |
| Operating Expenses | $1,925 | $1,609 |
| Net Loss | $(1,640) | $(1,571) |
| Net Loss Per Share (Basic/Diluted) | $(0.04) | $(0.13) |
| Cash and Cash Equivalents (End of Period) | $2,505 | $413 |
| Total Assets | $8,761 | $10,085 |
| Accumulated Deficit | $(83,252) | $(81,612) |
Liquidity: Cash and cash equivalents decreased by $944,000 during the quarter. The company holds $4.3 million in Auction Rate Securities (ARS), which have been reclassified as non-current assets due to failed auctions and lack of liquidity.
Material Changes vs. Prior Period
- Revenue Growth: Net product revenues increased 31% to $387,000, driven by an 8% increase in unit sales of the OLpůr MDHDF filter series in Europe, favorable currency translation, and $23,000 in revenue from a U.S. Naval Research contract.
- Expense Increases: Research and Development (R&D) expenses surged 86% to $723,000, primarily due to a $360,000 increase in clinical trial expenses for the H2H module.
- Impairment Charge: The company recorded a $114,000 impairment loss on Auction Rate Securities (ARS) due to failed auctions and liquidity issues in the credit markets.
- Stock-Based Compensation: Decreased significantly from $187,000 in Q1 2007 to $32,000 in Q1 2008.
- Debt Status: The company had no interest expense in Q1 2008 as all convertible notes were converted to equity in late 2007.
Outlook, Risks, and Management Commentary
- Liquidity Risk: Management states that financial resources excluding ARS are sufficient to fund operations through the third quarter of 2008. However, the company is exploring loans secured by ARS to gain liquidity. If liquidity cannot be obtained from ARS or other sources, the company may run out of funds.
- ARS Liquidity Crisis: ARS auctions have failed since February 2008. These assets are currently illiquid and may not be accessible until maturity (2040/2043) or a successful auction occurs.
- Listing Compliance: The company resolved deficiencies with the American Stock Exchange (AMEX) regarding shareholder equity in March 2008. However, failure to generate revenue or raise capital could lead to future non-compliance and potential delisting.
- Internal Controls: Management identified a material weakness in internal controls due to insufficient accounting resources, resulting in ineffective review of financial statements. Remediation plans are underway.
- Executive Changes: Mark W. Lerner resigned as CFO in April 2008 and was replaced by Gerald J. Kochanski.
Investor Verification Checklist
- Runway Analysis: Verify if the company can sustain operations through Q3 2008 without liquidating ARS or raising new capital.
- ARS Valuation: Monitor the status of Auction Rate Securities auctions and potential for further impairment charges beyond the $114,000 already recorded.
- Clinical Trial Progress: Confirm the timeline for the completion of the H2H clinical trials and the subsequent 510(k) submission to the FDA.
- AMEX Compliance: Track shareholder equity levels to ensure continued compliance with AMEX listing standards.
- Internal Control Remediation: Assess the progress of hiring qualified accounting staff and implementing new closing procedures to address the material weakness.